Crossmark

Practical issues in clinical scenarios involving CKD patients requiring antithrombotic therapy in light of the 2017 ESC guideline recommendations

Crossref DOI link: https://doi.org/10.1186/s12916-018-1145-0

Published Online: 2018-09-19

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Covic, Adrian

Genovesi, Simonetta

Rossignol, Patrick

Kalra, Philip A.

Ortiz, Alberto

Banach, Maciej

Burlacu, Alexandru https://orcid.org/0000-0002-3424-1588
License Information

Text and Data Mining valid from 2018-09-19
More Information

Article History

Received: 11 April 2018

Accepted: 3 August 2018

First Online: 19 September 2018

Ethics approval and consent to participate

: Not applicable.

: Not applicable.

: AC speaker and consulting fees for Vifor-Fresenius, Otsuka, and Roche. SG speaker fees for Boeringher and Shire. AO consultant for Sanofi Genzyme and Servier, and speaker fees for Amgen, Shire, and Otsuka. PR speaker and consulting fees for Astra-Zeneca, Bayer, Novartis, Relypsa, Stealth Peptides, and Vifor Fresenius Medical Care Renal Pharma, and co-founder of CardioRenal. MB speaker fees for Amgen, Abbott, Actavis, KRKA, MSD, Mylan, and Sanofi. AB speaker fees for Astra Zeneca, Sanofi, Boeringher Ingelheim, and Pfizer. None of these companies influenced this work.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.